TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18003667

Group type: EXPERIMENTAL
Intervention: Iodine nutritional status assessment
Number of subjects: 1627

Group type: EXPERIMENTAL
Intervention: Environmental iodine sufficiency assessment
Number of subjects: 1627

Group type: EXPERIMENTAL
Intervention: Assessment of dietary factors
Number of subjects: 1627
Study: 16649871

Group type: EXPERIMENTAL
Intervention: Dissonance intervention
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Healthy weight management intervention
Number of subjects: 481

Group type: COMPARATOR
Intervention: Expressive writing control condition
Number of subjects: 481

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Dissonance and healthy weight interventions
Number of subjects: 481
Study: 14614004

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry (IHC)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization (FISH)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: ELISA
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: IHC 3+
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: IHC 2+
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Adenocarcinomas
Number of subjects: 563
Study: 10721197

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 180

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 180
Study: 9124849

Group type: EXPERIMENTAL
Intervention: Balofloxacin (Q‐35)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grepafloxacin (OPC‐17116)
Number of subjects: 0
Study: 1312770

Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous therapy
Number of subjects: 20
Study: 3889148

Group type: EXPERIMENTAL
Intervention: Potassium chloride (100 mmol/day for 2 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Potassium loading (100 mmol/day for 5 days) in normal subjects
Number of subjects: 33
Study: 30321224

Group type: EXPERIMENTAL
Intervention: Dat-e Adolescence program (experimental group)
Number of subjects: 1764

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1764
Study: 27107475

Group type: EXPERIMENTAL
Intervention: Fresh frozen bone allograft (FFB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bovine bone mineral (BBM)
Number of subjects: 30
Study: 24174612

Group type: EXPERIMENTAL
Intervention: Motivational enhancement treatment plus brief physician advice and 8 weeks of nicotine replacement therapy (NRT)
Number of subjects: 846

Group type: COMPARATOR
Intervention: Standard care (brief physician advice and 8 weeks of NRT)
Number of subjects: 846
Study: 22561511

Group type: EXPERIMENTAL
Intervention: Unpleasant-negative appraisal frame
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pleasant-positive appraisal frame
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unpleasant-neutral appraisal frame
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pleasant-neutral appraisal frame
Number of subjects: 20
Study: 20593912

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol fixed maintenance dose (640 microg/18 microg per day)
Number of subjects: 2866

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy (320 microg/9 microg per day plus additional inhalations as needed)
Number of subjects: 2866

Group type: COMPARATOR
Intervention: Salmeterol/fluticasone propionate fixed maintenance dose (100 microg/500 microg per day plus terbutaline as needed)
Number of subjects: 2866

Group type: COMPARATOR
Intervention: Budesonide/formoterol maintenance and reliever therapy
Number of subjects: 2866

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 2866
Study: 19180837

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 8901

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8901
Study: 16254577

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 387
Study: 12153791

Group type: EXPERIMENTAL
Intervention: Silicone IOL
Number of subjects: 70

Group type: COMPARATOR
Intervention: Acrylic IOL
Number of subjects: 70
Study: 10098429

Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative radiotherapy (conventional roentgen, electron beams, and high‐energy photon beams) with a target dose of 38‐48 Gy, administered in daily fractions of 1.9‐2.4 Gy, 5 days/week.
Number of subjects: 90

Group type: COMPARATOR
Intervention: No radiotherapy (control group).
Number of subjects: 90
Study: 7726817

Group type: EXPERIMENTAL
Intervention: Social skills instruction (modeling, role playing, corrective feedback, differential reinforcement) with parental involvement
Number of subjects: 5
Study: 1974513

Group type: EXPERIMENTAL
Intervention: Acute administration of 50 mg carvedilol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic administration of carvedilol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7361266

Group type: EXPERIMENTAL
Intervention: External pneumatic compression (EPC) of the calves applied in the operating room and recovery room
Number of subjects: 0

Group type: COMPARATOR
Intervention: External pneumatic compression (EPC) continued during convalescence until resumption of ambulation
Number of subjects: 0
Study: 31254190

Group type: EXPERIMENTAL
Intervention: On-demand film
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insert
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monthly ring
Number of subjects: 0
Study: 30478094

Group type: EXPERIMENTAL
Intervention: Carfilzomib and dexamethasone (Kd56)
Number of subjects: 929

Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone (Vd)
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: Combined Kd56 and Vd analysis
Number of subjects: 929
Study: 28759403

Group type: EXPERIMENTAL
Intervention: Metformin 1 g/d for 6 months
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 160
Study: 25050872

Group type: COMPARATOR
Intervention: Group intervention
Number of subjects: 33

Group type: COMPARATOR
Intervention: Individual intervention
Number of subjects: 33
Study: 23771713

Group type: EXPERIMENTAL
Intervention: Percutaneous cardiac intervention (PCI)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 138

Group type: COMPARATOR
Intervention: Conservative drug therapy
Number of subjects: 138

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 138
Study: 21649784

Group type: EXPERIMENTAL
Intervention: Living serum‐free cultured epidermal autograft with wound-area debridement and a four-layer compression wrap (N=10)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Wound-area debridement and a four-layer compression wrap (Control group, N=5)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Living serum‐free cultured epidermal autograft
Number of subjects: 15
Study: 20297707

Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional Restorative Treatment (CRT)
Number of subjects: 40
Study: 15654267

Group type: EXPERIMENTAL
Intervention: Terbutaline (10 microg/min, 20 microg/min, 30 microg/min)
Number of subjects: 6
Study: 12652148

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin infusion with bedside aPTT testing and computerized algorithmic adjustment
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Achieving target aPTT
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: In-range aPTTs
Number of subjects: 1275
Study: 10408490

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7742156

Group type: EXPERIMENTAL
Intervention: New microemulsion oral formulation (NEO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Soft gelatine capsule (SGC)
Number of subjects: 12
Study: 2342981

Group type: EXPERIMENTAL
Intervention: Nursing consultation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Health education
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study: 6770400

Group type: EXPERIMENTAL
Intervention: 10 mg oral methadone
Number of subjects: 0
Study: 30414865

Group type: EXPERIMENTAL
Intervention: Financial incentives for research participation
Number of subjects: 576
Study: 28319494

Group type: EXPERIMENTAL
Intervention: Plasma HBP levels
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Recombinant HBP
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Heparin derivatives
Number of subjects: 296
Study: 26552068

Group type: EXPERIMENTAL
Intervention: 1.2% simvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.2% atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: SRP only (control)
Number of subjects: 0
Study: 24640583

Group type: EXPERIMENTAL
Intervention: RLX (40 mcg/d) plus rehabilitation
Number of subjects: 36
Study: 21878434

Group type: EXPERIMENTAL
Intervention: Darexaban 10 mg o.d.
Number of subjects: 1279

Group type: EXPERIMENTAL
Intervention: Darexaban 30 mg b.i.d.
Number of subjects: 1279

Group type: EXPERIMENTAL
Intervention: Darexaban 60 mg o.d.
Number of subjects: 1279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1279
Study: 19689801

Group type: EXPERIMENTAL
Intervention: Telephone-delivered lifestyle intervention focusing on symptom management, lifestyle and psychosocial support, delivered over 6 months with up to 11 sessions.
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control condition (details not specified in the abstract).
Number of subjects: 350
Study: 17492272

Group type: EXPERIMENTAL
Intervention: 20 mg intravenous citalopram
Number of subjects: 90
Study: 15364775

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody recognizing IL-8 (800-mg loading dose; 400-mg subsequent doses)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo (active buffer solution)
Number of subjects: 109
Study: 11277373

Group type: EXPERIMENTAL
Intervention: Routine daily chest radiographs
Number of subjects: 30
Study: 9766831

Group type: EXPERIMENTAL
Intervention: Oral appliances for the management of chronic myalgia of the jaw muscles
Number of subjects: 0
Study: 8018358

Group type: EXPERIMENTAL
Intervention: Fast neutron therapy
Number of subjects: 0
Study: 2596599

Group type: EXPERIMENTAL
Intervention: Prednisone (20 mg three times daily for 5 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no prednisone)
Number of subjects: 8
Study: 4119162

Group type: EXPERIMENTAL
Intervention: Ragweed extract immunotherapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31692660

Group type: EXPERIMENTAL
Intervention: Improved invitation letter and two self-testing kits (Arm 3)
Number of subjects: 1410

Group type: COMPARATOR
Intervention: Improved invitation letter (Arm 2)
Number of subjects: 1410

Group type: COMPARATOR
Intervention: Standard of care (Arm 1)
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: Arm 3 vs Arm 1
Number of subjects: 1410

Group type: COMPARATOR
Intervention: Arm 2 vs Arm 1
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: Arm 3 vs Arm 2
Number of subjects: 1410
Study: 26184103

Group type: EXPERIMENTAL
Intervention: Conventional resistance training
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Isokinetic resistance training
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 25258175

Group type: EXPERIMENTAL
Intervention: Teleconsultation (TCA)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Outpatient consultation (OCA)
Number of subjects: 69
Study: 23290075

Group type: EXPERIMENTAL
Intervention: Herbal medicine (Shaofu Zhuyu formula concentrated-granule, SFZYFG) therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 35
Study: 21224776

Group type: EXPERIMENTAL
Intervention: One-level instrumented posterolateral fusion with local bone graft
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Two-level instrumented posterolateral fusion with local bone graft
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Three-level instrumented posterolateral fusion with local bone graft
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) score
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Japanese Orthopedic Association Score (JOAS)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Oswestry Disability Index (ODI)
Number of subjects: 122
Study: 18442638

Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Metformin (0.5 g 3 times a day)
Number of subjects: 84
Study: 15890685

Group type: EXPERIMENTAL
Intervention: AMD3100 plus G-CSF (A + G)
Number of subjects: 0

Group type: COMPARATOR
Intervention: G-CSF alone (G)
Number of subjects: 0
Study: 11641591

Group type: EXPERIMENTAL
Intervention: Fluindione plus aspirin (100 mg)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Fluindione plus placebo (anticoagulant alone)
Number of subjects: 157
Study: 9617462

Group type: EXPERIMENTAL
Intervention: r‐hEPO 100 IU/kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: r‐hEPO 200 IU/kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: r‐hEPO 400 IU/kg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: r‐hEPO (all doses)
Number of subjects: 13
Study: 8075028

Group type: EXPERIMENTAL
Intervention: Mitomycin-vindesine-cisplatin (MVP)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Mitomycin-ifosfamide-cisplatin (MIP)
Number of subjects: 196
Study: 2609991

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg thrice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31889306

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 29524398

Group type: EXPERIMENTAL
Intervention: FES-cycling
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo FES-cycling
Number of subjects: 23
Study: 27625301

Group type: EXPERIMENTAL
Intervention: MK‐7 375 µg for 12 months
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 24927275

Group type: EXPERIMENTAL
Intervention: TE5 acupuncture (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham acupuncture (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nonacupoint acupuncture (n = 12)
Number of subjects: 24
Study: 22425005

Group type: EXPERIMENTAL
Intervention: External laryngeal manipulation (ELM)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard intubation (control)
Number of subjects: 27
Study: 19962839

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care provided at month 2
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard pharmacy services (Control)
Number of subjects: 180
Study: 17823597

Group type: EXPERIMENTAL
Intervention: Contemplative meditation combined with breathing techniques (CMBT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 52
Study: 15751670

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 200 mg added to 500 mL NaCl and perfused for 180 min after induction of anaesthesia and 100 mg PTX added to warm cardioplegic solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (saline solution as placebo)
Number of subjects: 60
Study: 11384690

Group type: EXPERIMENTAL
Intervention: Pediatric Foley catheter test
Number of subjects: 173
Study: 9731907

Group type: EXPERIMENTAL
Intervention: Dexamethasone and tropisetron
Number of subjects: 300

Group type: COMPARATOR
Intervention: Dexamethasone and placebo
Number of subjects: 300
Study: 7994827

Group type: EXPERIMENTAL
Intervention: 6-step protocol using four extrastimuli
Number of subjects: 209

Group type: COMPARATOR
Intervention: 18-step protocol using one, two, and three extrastimuli
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: 6-step protocol
Number of subjects: 209

Group type: COMPARATOR
Intervention: 18-step protocol
Number of subjects: 209
Study: 2493732

Group type: EXPERIMENTAL
Intervention: Continuous nitroglycerin therapy (active drug patches worn for 24 hours)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intermittent nitroglycerin therapy (12-hour active drug followed by 12-hour nitrate-free period)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30042975

Group type: EXPERIMENTAL
Intervention: Arterial phase CT imaging
Number of subjects: 32

Group type: COMPARATOR
Intervention: Portal venous (PV) phase imaging
Number of subjects: 32
Study: 25741640

Group type: EXPERIMENTAL
Intervention: Insulin glargine administered with SoloSTAR® or ClikSTAR® pens
Number of subjects: 327
Study: 23663317

Group type: EXPERIMENTAL
Intervention: iPad-based play audiometer
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard play audiometry
Number of subjects: 85
Study: 21124328

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 57
Study: 19455340

Group type: EXPERIMENTAL
Intervention: Radical retropubic prostatectomy (RRP)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Brachytherapy (BT)
Number of subjects: 200
Study: 17185119

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acetaminophen and Ibuprofen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15379308

Group type: EXPERIMENTAL
Intervention: Periocline (2% minocycline hydrochloride ointment)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Yakang (local metronidazole)
Number of subjects: 11
Study: 11179058

Group type: EXPERIMENTAL
Intervention: Metronome-guided breathing
Number of subjects: 39

Group type: COMPARATOR
Intervention: Spontaneous breathing
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Metronome-guided breathing (increasing rates from 9 to 20 breaths/min)
Number of subjects: 39
Study: 9771304

Group type: EXPERIMENTAL
Intervention: Tropisetron 0.1 mg kg‐1
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 8160137

Group type: EXPERIMENTAL
Intervention: Reaferon (1 x 10(6) IU, once a week, i.m. for 2 months)
Number of subjects: 30
Study: 29752027

Group type: EXPERIMENTAL
Intervention: Setting-wide positive behaviour support (SWPBS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (individualized PBS access)
Number of subjects: 24
Study: 27766453

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) use
Number of subjects: 707
Study: 24835495

Group type: EXPERIMENTAL
Intervention: Covert vigilant attention task with EEG monitoring
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EEG activity in the α-frequency range (8-14 Hz)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: P3 event-related component
Number of subjects: 12
Study: 21868176

Group type: EXPERIMENTAL
Intervention: Classroom-centered (CC) intervention
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Family-school partnership (FSP) intervention
Number of subjects: 678

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 678
Study: 20189754

Group type: EXPERIMENTAL
Intervention: MET hospitals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 0
Study: 18332472

Group type: EXPERIMENTAL
Intervention: Exemestane (25 mg/d orally)
Number of subjects: 1598

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1598
Study: 16567978

Group type: EXPERIMENTAL
Intervention: MMRV, Hib/HepB, and DTaP concomitantly
Number of subjects: 1915

Group type: EXPERIMENTAL
Intervention: MMRV followed by Hib/HepB and DTaP 42 days later
Number of subjects: 1915

Group type: COMPARATOR
Intervention: MMR and varicella vaccine followed by Hib/HepB and DTaP 42 days later
Number of subjects: 1915
Study: 14562776

Group type: EXPERIMENTAL
Intervention: Totally intravenous anaesthesia (propofol and remifentanil)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Mixed anaesthesia (isoflurane and fentanyl)
Number of subjects: 53
Study: 10801250

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.6 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Lactate capsule (control)
Number of subjects: 9
Study: 8721077

Group type: EXPERIMENTAL
Intervention: Ritipenem acoxil (RIPM-AC)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Cefotiam hexetil (CTM-HE)
Number of subjects: 208
Study: 1558072

Group type: EXPERIMENTAL
Intervention: Nebulized metaproterenol
Number of subjects: 74

Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 74
Study: 3912190

Group type: EXPERIMENTAL
Intervention: Baclofen 10 mg orally
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Elderly stroke patients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups (elderly stroke patients and healthy controls)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Simulations based on mean data
Number of subjects: 12
Study: 31314965

Group type: EXPERIMENTAL
Intervention: Group A (combination prevention intervention with universal antiretroviral therapy [ART])
Number of subjects: 48301

Group type: EXPERIMENTAL
Intervention: Group B (prevention intervention with ART provided according to local guidelines)
Number of subjects: 48301

Group type: COMPARATOR
Intervention: Group C (standard care)
Number of subjects: 48301
Study: 29850026

Group type: EXPERIMENTAL
Intervention: Positive Choices intervention (student needs survey, SHPC, classroom curriculum, student-led marketing, parent information, review of services)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (two schools without the Positive Choices intervention)
Number of subjects: 6
Study: 26897656

Group type: EXPERIMENTAL
Intervention: CHARM intervention (multi-session gender-equity focused family planning program)
Number of subjects: 1081
Study: 24724863

Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusions at counts of fewer than 10 × 10(9) /L
Number of subjects: 600

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 600
Study: 22607479

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort Turbuhaler SMART™), starting dose 160 mg/4.5 mg two inhalations twice daily plus as-needed inhalations
Number of subjects: 404

Group type: COMPARATOR
Intervention: Salmeterol/fluticasone propionate (Seretide Diskus), starting dose 50 mg/250 mg bid plus salbutamol as needed
Number of subjects: 404